

Alumis IPO Priced at $16, Targets $210M Funding
Alumis, a clinical-stage immunology biotech company, has priced its downsized

Unlocking New Frontiers: How Generative AI is Transforming Protein Design and Drug Discovery
Abstract This report explores the transformative impact of generative artificial
